N4 Pharma plc (LON:N4P) are a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that it has raised £2 million (before expenses) through
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided the following update on its ongoing research collaboration agreement
N4 Pharma plc (LON:N4P) is the topic of conversation when SP Angel Analyst and Head of Healthcare Vadim Alexandre joins DirectorsTalk. Vadim having just initiated on the company explains what N4P
N4 Pharma’s Nigel Theobald discusses their latest operational update, the importance of demonstrating formulation, key milestones for the COVID-19 proof of concept programme, whyan orally administered vaccine has greater challenges than a subcutaneous injection and what news flow investors can expect from the company for the rest of the year in this exclusive interview with DirectorsTalk.
N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss its latest operational update. Nigel talks us through the key highlights, explains why demonstrating formulation stability is so important, the
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that it has appointed Nanomerics Limited to investigate the potential
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided the following update on its ongoing work programmes. Optimisation
Confirmed COVID-19 cases are in the millions, and with hundreds of thousands of deaths from the disease the social, healthcare and economic consequences are likely to persist for years. While drug
N4 Pharma’s Nigel Theobald discusses H1 highlights, their new refined strategy, how the COVID pandemic created opportunities for the business and what investors can expect for the rest of the year in this exclusive interview with DirectorsTalk.
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
